<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00728299</url>
  </required_header>
  <id_info>
    <org_study_id>Radiant Development #202528</org_study_id>
    <nct_id>NCT00728299</nct_id>
  </id_info>
  <brief_title>The Effects of Consumption of Pomegranate Juice on Carotid Intima-Media Thickness</brief_title>
  <official_title>The Effects of Consumption of Pomegranate Juice on Carotid Intima-Media Thickness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiant Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roll International Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiant Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increases in carotid artery intima-media thickness (IMT) are correlated with increased risk&#xD;
      of stroke and myocardial infarction. The purpose of this study is to assess if pomegranate&#xD;
      juice will retard the carotid (IMT) progression rate in men and women who have one or more&#xD;
      existing cardiovascular risk factors (current cigarette smoking, hypertension, low&#xD;
      HDL-cholesterol, and/or high LDL-cholesterol) upon entrance into the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies in atherosclerotic mice have shown that pomegranate supplementation reduced&#xD;
      their macrophage oxidative stress and attenuated the development of their atherosclerosis.&#xD;
      Further research in hypertensive humans demonstrated that pomegranate juice had an&#xD;
      angiotensin converting enzyme (ACE)-inhibitory effect and significantly decreased systolic&#xD;
      blood pressure.&#xD;
&#xD;
      This study will use a randomized, double-blind, placebo-controlled design with eight clinic&#xD;
      visits (one screening visit [week -4 to -1], one baseline visit [week 0], and six treatment&#xD;
      visits [weeks 13, 26, 38, 52, 65, and 78]).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in posterior wall common carotid intima-media thickness (IMT) progression rate in mm/yr between PomWonderful juice and placebo, utilizing non-contrast images</measure>
    <time_frame>78-90 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference between placebo and PomWonderful juice in internal carotid artery IMT progression rate in mm/yr</measure>
    <time_frame>78-90 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between placebo and PomWonderful juice in the carotid bifurcation IMT progression rate in mm/yr</measure>
    <time_frame>78-90 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between placebo and PomWonderful juice in the anterior wall common carotid IMT progression rate in mm/yr, without contrast agent</measure>
    <time_frame>78-90 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between placebo and PomWonderful juice in the anterior wall common carotid IMT progression rate in mm/yr, with contrast agent</measure>
    <time_frame>78-90 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between placebo and PomWonderful juice in the posterior wall common carotid IMT progression rate in mm/yr, with contrast agent</measure>
    <time_frame>78-90 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between placebo and PomWonderful juice in the composite IMT measure, which combines the measurements of the common and internal carotid and the carotid bifurcation in mm/yr</measure>
    <time_frame>78-90 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to 13 weeks in hs-CRP concentration</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">384</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PomWonderful Juice</intervention_name>
    <description>8 oz per day each day for 78 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo juice</intervention_name>
    <description>8 oz per day for 78 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males between the ages of 45 and 74 and females between the ages of 55 and 74 years.&#xD;
&#xD;
          -  Subject has ≥ 1 of the following risk factors at Visit 1 (week -4 to -1):&#xD;
&#xD;
               -  current cigarette smoking (defined as any cigarette smoking within the past&#xD;
                  month)&#xD;
&#xD;
               -  hypertension (blood pressure ≥ 140/90 mm Hg or using an antihypertensive&#xD;
                  medication)&#xD;
&#xD;
               -  low HDL cholesterol (&lt; 40 mg/dL)&#xD;
&#xD;
               -  high LDL cholesterol (≥ 130 mg/dL and &lt; 190 mg/dL), on statin therapy or not&#xD;
&#xD;
          -  Posterior wall common carotid IMT &gt; 0.7 mm and &lt; 2.0 mm at Visit 2 (week 0) with an&#xD;
             adequate image on at least one side.&#xD;
&#xD;
          -  Subject understands the study procedures and signs an informed consent form.&#xD;
&#xD;
          -  Normally active and judged to be in good health on the basis of medical history,&#xD;
             physical examination, and routine laboratory tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any pharmacologic lipid-altering medications, besides statins (e.g., fibrate&#xD;
             derivatives, bile acid binding resins, and niacin or its analogues at doses &gt; 400&#xD;
             mg/d) six weeks prior to Visit 1&#xD;
&#xD;
          -  Body mass index &gt; 40 kg/m2.&#xD;
&#xD;
          -  Unstable use (&lt; 2 months prior to Visit 1) of any supplement known to alter lipid&#xD;
             metabolism, including but not limited to: dietary fiber supplements (including &gt; 2&#xD;
             teaspoons Metamucil® or psyllium-containing supplement per day), omega-3 fatty acid&#xD;
             supplements, sterol/stanol products, red rice yeast supplements, garlic supplements,&#xD;
             soy isoflavone supplements or others at the discretion of the Investigator).&#xD;
&#xD;
          -  History of pomegranate consumption (either eating pomegranates or drinking pomegranate&#xD;
             juice) within the past 6 months.&#xD;
&#xD;
          -  Clinical evidence or history of coronary heart disease (CHD) or CHD equivalents&#xD;
             including:&#xD;
&#xD;
               -  diabetes mellitus,&#xD;
&#xD;
               -  angina,&#xD;
&#xD;
               -  myocardial infarction,&#xD;
&#xD;
               -  transient ischemic attack,&#xD;
&#xD;
               -  symptomatic carotid artery disease,&#xD;
&#xD;
               -  cerebrovascular accident,&#xD;
&#xD;
               -  coronary artery bypass grafting,&#xD;
&#xD;
               -  percutaneous transluminal coronary angioplasty,&#xD;
&#xD;
               -  peripheral arterial disease,&#xD;
&#xD;
               -  abdominal aortic aneurysm,&#xD;
&#xD;
               -  ankle brachial index &lt; 0.90,&#xD;
&#xD;
               -  and/or a Framingham Risk Score ≥ 16 points for men and ≥ 23 points for women&#xD;
                  (10-year CHD risk &gt; 20%)&#xD;
&#xD;
          -  Active cancer, other than non-melanoma skin cancer, within the previous two years.&#xD;
&#xD;
          -  Prior diagnosis of human immunodeficiency virus (HIV) or hepatitis B or hepatitis C.&#xD;
&#xD;
          -  Uncontrolled hypertension (average systolic blood pressure ≥ 160 mm Hg and/or average&#xD;
             diastolic blood pressure ≥ 100 mm Hg).&#xD;
&#xD;
          -  Untreated or unstable hypothyroidism (receiving stable dose therapy for &lt; 4.0 months).&#xD;
&#xD;
          -  Concomitant use of beta-adrenergic blockers or immunosuppressants&#xD;
&#xD;
          -  Concomitant use of estrogen or progestin therapy.&#xD;
&#xD;
          -  Allergy to pomegranates or pomegranate juice.&#xD;
&#xD;
          -  Known allergy to blood products.&#xD;
&#xD;
          -  Non-English speaking.&#xD;
&#xD;
          -  Active liver disease or hepatic dysfunction as defined by elevations of ≥ 2.0 x ULN at&#xD;
             Visit 1 in any of the following liver function tests: ALT, AST or bilirubin.&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0 mg/dL recorded during screening period.&#xD;
&#xD;
          -  Recent history of (within past 12 months) or strong potential for alcohol or substance&#xD;
             abuse. Alcohol abuse will be defined as &gt;14 drinks per week (1 drink = 12 oz beer, 4&#xD;
             oz wine, or 1 ½ oz distilled spirits).&#xD;
&#xD;
          -  Participation in another clinical study within 30 days prior to screening visit 1&#xD;
             (week -4 to -1).&#xD;
&#xD;
          -  Has a condition the Investigator believes would interfere with evaluation of the&#xD;
             subject, or may put subject at undue risk.&#xD;
&#xD;
          -  Posterior wall common carotid IMT ≥ 2.0 mm on either side at Visit 2 (week 0).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Davidson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FACC</affiliation>
  </overall_official>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>July 31, 2008</study_first_submitted>
  <study_first_submitted_qc>August 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2008</study_first_posted>
  <last_update_submitted>August 4, 2008</last_update_submitted>
  <last_update_submitted_qc>August 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>Michael H. Davidson, MD, Executive Medical Director,</name_title>
    <organization>Radiant Research</organization>
  </responsible_party>
  <keyword>Coronary artery disease, carotid intima-media thickness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

